Histone deacetylase inhibitor MGCD0103 synergizes with gemcitabine in human pancreatic cells

Cancer Science

Volumn 102, Issue 6, 2011, Pages 1201-1207

  Sung, Victoria ^a   Richard, Normand ^b   Brady, Helen ^b   Maier, Armin ^c   Kelter, Gerhard ^c   Heise, Carla ^a  

^a Celgene   (United States)

^b CELGENE CORPORATION   (United States)

^c CHARLES RIVER LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; MOCETINOSTAT; PROTEIN P21;

ARTICLE; CANCER INHIBITION; CELL ANCHORAGE; CELL CYCLE; CELL GROWTH; CELL VIABILITY; CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; GENE EXPRESSION; HUMAN; HUMAN CELL; PANCREAS CARCINOMA; PANCREAS CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

APOPTOSIS; BENZAMIDES; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; DRUG SYNERGISM; GENE EXPRESSION; HISTONE DEACETYLASE INHIBITORS; HUMANS; IMMUNOBLOTTING; PANCREAS; PANCREATIC NEOPLASMS; PYRIMIDINES;

EID: 79956198574     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.01921.x     Document Type: Article

References (38)

1. Hansel DE, Kern SE, Hruban RH. Molecular pathogenesis of pancreatic cancer. Annu Rev Genomics Hum Genet 2003; 4: 237-56.
2. Van Laethem J-L, Marechal R. Emerging drugs for the treatment of pancreatic cancer. Expert Opin Emerg Drugs 2007; 12 (2): 301-11.
3. Luger K, Mäder AW, Richmond RK et al. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 1997; 3889: 251-60.
4. Kouzarides T. Chromatin modifications and their function. Cell 2007; 128: 693-705.
5. Schrump DS. Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications. Clin Cancer Res 2009; 15: 3947-57.
6. Nakagawa M, Oda Y, Eguchi T et al. Expression profile of class I histone deacetylases in human cancer tissues. Oncol Rep 2007; 18: 769-74.
7. Sasaki H, Moriyama S, Nakashima Y et al. Histone deacetylase 1 mRNA expression in lung cancer. Lung Cancer 2004; 46: 171-8.
8. Miyake K, Yoshizumi T, Imura S et al. Expression of hypoxia-inducible factor-1alpha, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma: correlation with poor prognosis with possible regulation. Pancreas 2008; 36: e1-9.
9. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 769-84.
10. Burgess A, Ruefli A, Beamish H et al. Histone deacetylase inhibitors specifically kill nonproliferating tumour cells. Oncogene 2004; 23: 6693-701.
11. Xu J, Zhou JY, Wei WZ et al. Sp1-mediated TRAIL induction in chemosensitization. Cancer Res 2008; 68: 6718-26.
12. Arnold NB, Arkus N, Gunn J et al. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer. Clin Cancer Res 2007; 13: 18-26.
13. Garcia-Manero G, Assouline S, Cortes J et al. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 2008; 112: 981-9.
14. Siu LL, Pili R, Duran I et al. Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. J Clin Oncol 2008; 26: 1940-7.
15. Hurwitz H, Nelson B, O'Dwyer PJ et al. Phase I/II: The oral isotype-selective HDAC inhibitor MGCD0103 in combination with gemcitabine (Gem) in patients (pts) with refractory solid tumors. 2008 ASCO Annual Meeting Proceedings.
16. Reddig PJ, Juliano RL. Clinging to life: cell to matrix adhesion and cell survival. Cancer Metastasis Rev 2005; 24: 425-39.
17. Danen EH, Yamada KM. Fibronectin, integrins and growth control. J Cell Physiol 2001; 189: 1-13.
18. Chiarugi P, Giannoni E. Anoikis: a necessary death program for anchorage-dependent cells. Biochem Pharmacol 2008; 76: 1352-64.
19. Anderson SN, Towne DL, Burns DJ et al. A high-throughput soft agar assay for identification of anticancer compound. J Biomol Screen 2007; 12: 938-45.
20. Donadelli M, Constanzo C, Beghelli S et al. Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine. Biochim Biophys Acta 2007; 1773: 1095-106.
21. Piacentini P, Donadelli M, Costanzo C et al. Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation. Virchows Arch 2006; 448: 797-804.
22. Fournel M, Bonfils C, Hou Y et al. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther 2008; 7: 759-68.
23. Bonfils C, Kalita A, Dubay M et al. Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay. Clin Cancer Res 2008; 14: 3441-9.
24. Zhou N, Moradei O, Raeppel S et al. Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino) methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor. J Med Chem 2008; 51: 4072-5.
25. Raeppel S, Zhou N, Gaudette F et al. SAR and biological evaluation of analogues of a small molecule histone deacetylase inhibitor N-(2-aminophenyl)-4-((4-(pyridin-3-yl)pyrimidin-2-ylamino)methyl)benzamide (MGCD0103). Bioorg Med Chem Lett 2009; 19: 644-9.
26. Blum KA, Advani A, Fernandez L et al. Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia. Br J Haematol 2009; 147: 507-14.
27. Bociek RG, Kuruvilla J, Pro B et al. Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin Lymphoma (HL). 2008 ASCO Annual Meeting Proceedings.
28. Crump M, Andreadis C, Assouline S et al. Treatment of relapsed or refractory non-hodgkin lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: Interim results from a phase II study. 2008 ASCO Annual Meeting Proceedings.
29. Galmarini CM, Clarke ML, Falette N et al. Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine. Int J Cancer 2002; 97: 439-45.
30. Clarke ML, Mackey JR, Baldwin SA et al. The role of membrane transporters in cellular resistance to anticancer nucleoside drugs. Cancer Treat Res 2002; 112: 27-47.
31. Neff T, Blau CA. Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine. Exp Hematol 1996; 24: 1340-6.
32. Goan YG, Zhou B, Hu E et al. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2, 2-difluorodeoxycytidine in the human KB cancer cell line. Cancer Res 1999; 59: 4204-7.
33. Huang L, Sowa Y, Sakai T et al. Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites. Oncogene 2002; 19: 5712-9.
34. Donadelli M, Costanzo C, Faggioli L et al. Trichostatin A, an inhibitor of histone deacetylases, strongly suppresses growth of pancreatic adenocarcinoma cells. Mol Carcinog 2003; 38: 59-69.
35. Tolis C, Peters GJ, Ferreira CG et al. Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines. Eur J Cancer 1999; 35: 796-807.
36. Ahmed W, Rahmani M, Dent P et al. The cyclin-dependent kinase inhibitor p21(CIP1/WAF1) blocks paclitaxel-induced G2M arrest and attenuates mitochondrial injury and apoptosis in p53-null human leukemia cells. Cell Cycle 2004; 3: 1305-11.
37. Jung YS, Qian Y, Chen X. Examination of the expanding pathways for the regulation of p21 expression and activity. Cell Signal 2010; 22: 1003-12.
38. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 2009; 9: 400-14.